Attached files

file filename
EX-10.19 - EXHIBIT 10.19 - AERIE PHARMACEUTICALS INCaeri12312016ex-1019.htm
10-K - 10-K - AERIE PHARMACEUTICALS INCaeri-1231201610xk.htm
EX-32.2 - EXHIBIT 32.2 - AERIE PHARMACEUTICALS INCaeri12312016ex-322.htm
EX-32.1 - EXHIBIT 32.1 - AERIE PHARMACEUTICALS INCaeri12312016ex-321.htm
EX-31.2 - EXHIBIT 31.2 - AERIE PHARMACEUTICALS INCaeri12312016ex-312.htm
EX-31.1 - EXHIBIT 31.1 - AERIE PHARMACEUTICALS INCaeri12312016ex-311.htm
EX-21.1 - EXHIBIT 21.1 - AERIE PHARMACEUTICALS INCaeri12312016ex211.htm
EX-10.18.1 - EXHIBIT 10.18.1 - AERIE PHARMACEUTICALS INCaeri12312016ex-10181.htm
EX-10.17.1 - EXHIBIT 10.17.1 - AERIE PHARMACEUTICALS INCaeri12312016ex-10171.htm
EX-10.16.1 - EXHIBIT 10.16.1 - AERIE PHARMACEUTICALS INCaeri12312016ex-10161.htm
EX-10.21 - EXHIBIT 10.21 - AERIE PHARMACEUTICALS INCaeri12312016ex-1021.htm
EX-10.20 - EXHIBIT 10.20 - AERIE PHARMACEUTICALS INCaeri12312016ex-1020.htm
EX-4.1.1 - EXHIBIT 4.1.1 - AERIE PHARMACEUTICALS INCaeri12312016ex-411.htm


Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-213643 and No. 333-199821) and Form S-8 (No. 333-192030) of Aerie Pharmaceuticals, Inc. of our report dated March 9, 2017 relating to the consolidated financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Florham Park, NJ
March 9, 2017